Please contact us for more information or to learn if you are eligible to participate.
This study will evaluate the safety and efficacy of bacteriophage therapy in patients with urinary tract infection (UTI). Patients to be enrolled must have urinary tract infections due to E. coli and K. pneumoniae. This will include asymptomatic patients with neurogenic bladder and symptomatic patients with complicated urinary tract infections who are at risk of UTI recurrence. Patients will be followed for bacterial clearance or recurrence of urinary tract infection.
Roberto Cruz-Saldana, MD
Adaptive Phage Therapeutics, Inc.
Type of Trial